Know Cancer

or
forgot password

Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia


N/A
18 Years
60 Years
Not Enrolling
Both
Leukemia, Lymphocytic, Chronic

Thank you

Trial Information

Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia


To determine effectiveness of allogeneic transplantation in eradicating chronic lymphocytic
leukemia.


Inclusion Criteria:

- adequate organ function - normal bone marrow cytogenetics

Exclusion Criteria:- active CNS disease

- For autologous patients more than 30% bone marrow involvement

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy

Outcome Time Frame:

unknown

Safety Issue:

No

Principal Investigator

Robert S Negrin

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

BMT88

NCT ID:

NCT00186303

Start Date:

November 1996

Completion Date:

March 2010

Related Keywords:

  • Leukemia, Lymphocytic, Chronic
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid

Name

Location

Stanford University School of MedicineStanford, California  94305-5317